MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-17-2026
AlloVir ROE Ratio 2011-2026 | ALVR
Annual ROE Ratio AlloVir
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -55.11 | 71.59 | -130.62 | -75.14 | -76.34 | -19.77 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71.59 | -130.62 | -47.56 |
Quarterly ROE Ratio AlloVir
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -23.13 | 47.89 | 80.22 | 60.74 | 38.08 | -27.2 | -57.92 | -63.7 | -80.32 | -74.27 | -82.74 | -67.73 | -84.75 | -85.16 | -69.36 | -38.81 | -45.5 | -35.16 | -26.03 | -12.63 | 1.49 | 22.29 | 35.88 | 32.08 | 32.08 | 17.96 | 7.67 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 80.22 | -85.16 | -18.45 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M |  USA |
 |
Anika Therapeutics
ANIK
|
-38.95 | $ 14.21 | -0.42 % | $ 208 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Aileron Therapeutics
ALRN
|
-115.61 | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
-39.17 | $ 3.35 | -2.62 % | $ 295 M | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 216.26 | -0.83 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 19.12 | -0.57 % | $ 894 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-123.35 | $ 0.62 | 2.14 % | $ 7.1 M |  Israel |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-30.26 | $ 46.45 | -0.91 % | $ 4.18 B |  Schweiz |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.4 | -0.36 % | $ 357 M | Britain |
 |
Exelixis
EXEL
|
36.21 | $ 41.13 | -0.69 % | $ 11.2 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
ChemoCentryx
CCXI
|
-46.05 | - | - | $ 3.74 B | USA |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.63 | - | $ 16.5 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-21.46 | $ 6.64 | -3.63 % | $ 421 K | USA |
 |
Atreca
BCEL
|
-123.92 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Genmab A/S
GMAB
|
24.88 | $ 25.59 | -0.35 % | $ 16.5 B | Danmark |
 |
Grifols, S.A.
GRFS
|
9.2 | $ 7.64 | -0.72 % | $ 6.83 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Halozyme Therapeutics
HALO
|
649.18 | $ 61.68 | -1.88 % | $ 7.39 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
18.24 | $ 26.99 | -2.21 % | $ 1.55 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-782.6 | - | -74.18 % | $ 955 K | USA |
 |
ImmuCell Corporation
ICCC
|
-7.84 | $ 6.43 | 0.31 % | $ 52.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Immatics N.V.
IMTX
|
1.79 | $ 9.32 | -2.0 % | $ 586 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
-46.9 | $ 69.48 | -1.85 % | $ 11.1 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-41.02 | $ 1.33 | -2.92 % | $ 235 M | France |
 |
Arbutus Biopharma Corporation
ABUS
|
-43.75 | $ 4.29 | -2.94 % | $ 822 M | Canada |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
-36.89 | - | 1.93 % | $ 17.4 M | USA |